ALNYLAM PHARMACEUTICALS, INC.
For the period ended Jun 30, 2025. Filed Jul 31, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 5. OTHER INFORMATION
Adoption of 10b5-1 Trading Plans by Our Officers and Directors
During our fiscal quarter ended June 30, 2025, certain of our officers (as defined in Rule 16a-1(f) under the Exchange Act) and directors entered into contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. We refer to these contracts, instructions, and written plans as “Rule 10b5-1 trading plans” and each as a “Rule 10b5-1 trading plan.” We describe the material terms of these Rule 10b5-1 trading plans below.
Dennis A. Ausiello, M.D., Director
On May 15, 2025, Dennis A. Ausiello, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Dr. Ausiello, acting through a broker, may sell up to an aggregate of 31,448 shares of our common stock received upon the exercise of options granted to Dr. Ausiello as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from August 13, 2025 to May 1, 2026. The plan is scheduled to terminate on May 1, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Ausiello or the broker, or as otherwise provided in the plan.
Colleen F. Reitan, Director
On June 10, 2025, Colleen F. Reitan, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Ms. Reitan, acting through a broker, may sell up to an aggregate of 18,000 shares of our common stock received upon the exercise of options granted to Ms. Reitan as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from September 9, 2025 to May 15, 2026. The plan is scheduled to terminate on May 15, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Ms. Reitan or the broker, or as otherwise provided in the plan.
Tolga Tanguler, Chief Commercial Officer
On May 27, 2025, Tolga Tanguler, our Chief Commercial Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Tanguler, acting through a broker, may sell up to an aggregate of 3,474 shares of our common stock received upon the settlement of awards granted to Mr. Tanguler as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from August 29, 2025 to May 10, 2026. The plan is scheduled to terminate on May 10, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Tanguler or the broker, or as otherwise provided in the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.